| Literature DB >> 35813710 |
Xiaogang Zhang1, Bei Tian1, Xinpeng Cong1, Shu-Wen Hao1, Qiang Huan1, Can Jin1, Luoning Zhu1, Zhong-Ping Ning1.
Abstract
Background: At present, the prediction of adverse events (AE) had practical significance in clinic and the accuracy of AE prediction model after left atrial appendage closure (LAAC) needed to be improved. To identify a good prediction model based on machine learning for short- and long-term AE after LAAC.Entities:
Keywords: Left atrial appendage closure (LAAC); adverse events (AE); machine learning; prediction
Year: 2022 PMID: 35813710 PMCID: PMC9264065 DOI: 10.21037/jtd-22-499
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Figure 1Computer-aided design evaluation of post-LAAC. LA, left atrium; LAAC, left atrial appendage closure.
Figure 2Transesophageal echocardiography and angiography before and after LAAC. (A) Baseline TEE; (B) LAAC TEE; (C) baseline angiography; (D) LAAC angiography. LAAC, left atrial appendage closure; TEE, transesophageal echocardiography.
Demographics and risk factors of included samples received LAAC surgery during 2016–2021
| Items | Adverse events | χ2/F | |
|---|---|---|---|
| Yes | No | ||
| Demographic | |||
| Gender | χ2=0.35 | ||
| Male | 20 | 496 | |
| Female | 11 | 342 | |
| Age, years | 74.9±9.09 | 74.12±9.13 | F=0.224 |
| BMI, kg/m2 | χ2=17.889* | ||
| <18.5 (underweight) | 13 | 124 | |
| 18.5–24.9 (normal) | 10 | 354 | |
| 25–29.9 (overweight) | 3 | 230 | |
| ≥30 (obese) | 6 | 129 | |
| Esophageal ultrasound | χ2=1.0731 | ||
| No abnormality | 28 | 698 | |
| Abnormality | 3 | 140 | |
| Risk factors | |||
| CHADS2 score | χ2=11.3186642 | ||
| 1 | 0 | 9 | |
| 2 | 1 | 38 | |
| 3 | 4 | 80 | |
| 4 | 5 | 140 | |
| 5 | 10 | 166 | |
| 6 | 0 | 167 | |
| 7 | 6 | 139 | |
| 8 | 5 | 81 | |
| 9 | 0 | 18 | |
| MI | χ2=0.44983 | ||
| Yes | 20 | 490 | |
| No | 11 | 348 | |
| Hyt | χ2=0.080142 | ||
| Yes | 25 | 658 | |
| No | 6 | 180 | |
| Age75 | χ2=0.12003 | ||
| Yes | 14 | 405 | |
| No | 17 | 433 | |
| DM | χ2=0.044022 | ||
| Yes | 7 | 203 | |
| No | 24 | 635 | |
| CI | χ2=1.654 | ||
| Yes | 19 | 415 | |
| No | 12 | 423 | |
| CVD | χ2=0.18003 | ||
| Yes | 25 | 700 | |
| No | 6 | 138 | |
| BLED score | χ2=5.232 | ||
| 0 | 0 | 22 | |
| 1 | 1 | 95 | |
| 2 | 7 | 205 | |
| 3 | 13 | 281 | |
| 4 | 8 | 195 | |
| 5 | 1 | 33 | |
| 6 | 1 | 7 | |
| Stroke | χ2=2.1593 | ||
| Yes | 19 | 401 | |
| No | 12 | 437 | |
| Hep | χ2=0.025743 | ||
| Yes | 1 | 23 | |
| No | 30 | 815 | |
| Ked | χ2=0.010886 | ||
| Yes | 1 | 30 | |
| No | 30 | 808 | |
| Blood | χ2=2.0396 | ||
| Yes | 1 | 96 | |
| No | 30 | 742 | |
| INR | χ2=0.07146 | ||
| Yes | 2 | 65 | |
| No | 29 | 773 | |
| Alc | χ2=0.75541 | ||
| Yes | 5 | 93 | |
| No | 26 | 745 | |
| Drug | χ2=0.052543 | ||
| Yes | 17 | 442 | |
| No | 14 | 396 | |
*P<0.05. LAAC, left atrial appendage closure; BMI, body mass index; CHADS2, congestive heart failure, hypertension, 75 years, diabetes, stroke/TIA, vascular disease, age 65 to 74 years, gender category (women); MI, history of myocardial infarction; Hyt, hypertension; age75, age over 75 years; DM, history of diabetes; CI, history of cerebral infarction; CVD, chronic heart disease; BLED score, bleeding score; Hep, liver injury; Ked, kidney disease; Blood, bleeding history; INR, international normalized ratio instability; Alc, drinking history.
Cox regression of complication in the initial follow-up and risk factors
| Variables | Coefficient | HR | SE of HR | Z | P value |
|---|---|---|---|---|---|
| Model fit | |||||
| Gender | −0.115 | 0.892 | 0.22 | −0.521 | 0.602444 |
| Weight | 0.0006 | 1.01 | 0.0004 | 1.459 | 0.144436 |
| Height | 0.0003 | 1.00 | 0.001 | 0.362 | 0.717353 |
| CHADS2 | 0.358 | 1.43 | 0.134 | 2.684 | 0.007279* |
| MI | −0.142 | 0.87 | 0.22 | −0.644 | 0.51986 |
| Hyt | 0.779 | 2.18 | 0.259 | 3.009 | 0.002618* |
| Age75 | −0.711 | 0.49 | 0.315 | −2.256 | 0.024064* |
| DM | −0.561 | 0.57 | 0.273 | −2.058 | 0.039596* |
| CI | −1.30 | 0.272 | 1.02 | −1.281 | 0.200046 |
| CVD | −0.088 | 0.916 | 0.255 | −0.344 | 0.730814 |
| BLED | −1.27 | 0.28 | 0.112 | −11.347 | <0.000002* |
| Stroke | 7.58 | 19.8 | 1.48 | 5.121 | 0.000000304* |
| Hep | 1.38 | 3.97 | 0.387 | 3.562 | 0.000368* |
| Ked | 1.07 | 2.93 | 0.37 | 2.903 | 0.003695* |
| Blood | 0.382 | 1.47 | 0.381 | 1.003 | 0.316057 |
| INR | 1.43 | 4.18 | 0.358 | 3.997 | 0.0000641* |
| Alc | 0.981 | 2.67 | 0.259 | 3.783 | 0.000155* |
| Drug | 0.859 | 2.36 | 0.224 | 3.84 | 0.000123* |
| Model evaluation | |||||
| Likelihood ratio test | 168.8 with P<0.05 | ||||
| Wald test | 185.8 with P<0.05 | ||||
| Logrank test | 264.3 with P<0.05 | ||||
*P<0.05. HR, hazard ratio; SE, standard error; CHADS2, congestive heart failure, hypertension, 75 years, diabetes, stroke/TIA, vascular disease, age 65 to 74 years, gender category (women); MI, history of myocardial infarction; Hyt, hypertension; age75, age over 75 years; DM, history of diabetes; CI, history of cerebral infarction; CVD, chronic heart disease; BLED score, bleeding score; Hep, liver injury; Ked, kidney disease; Blood, bleeding history; INR, international normalized ratio instability; Alc, drinking history.
Figure 3Forest plot of multiple risk factors. OR, odds ratio; CI, confidence interval; BMI, body mass index; MI, history of myocardial infarction; age75, age over 75 years; CHADS2, congestive heart failure, hypertension, 75 years, diabetes, stroke/TIA, vascular disease, age 65 to 74 years, gender category (women); Hyt, hypertension; BLED, bleeding; Hep, liver injury; Ked, kidney disease; INR, international normalized ratio; Alc, drinking history; DM, diabetes mellitus; CI, cerebral infarction; Blood, bleeding history.
Figure 4Comparison of 8 machine learning models for short-term AE. AE, adverse events.
Figure 5Accuracy of XGBoost in different iterations.
Figure 6ROC curve of XGBoost model for short-term AE. AUC, area under the curve; ROC, receiver operating characteristic; AE, adverse events.
Figure 7Plot in cumulative incidence of long-term AE. AE, adverse events.